摘要
炎症性肠病(inflammatory bowel disease,IBD)的病因和发病机制尚未完全明确。治疗措施包括水杨酸类制剂、糖皮质激素、免疫抑制剂、抗生素、生物治疗及手术切除等。随着基础免疫病理的研究深入和生物工程技术的发展,近年来出现重组人生长因子多肽药物试用于IBD的治疗。本文对该方面IBD治疗研究进展作一综述。
The etiology and pathgenesis of inflammatory bowel diseases（IBD） have not been fully clarified.Conventional therapies of IBD include five major categories,namely antiinflammatory drugs,corticosteroids,immuno-suppressants,antibiotics,biologic agents and surgical approaches.Alone with the progress of the immune pathology and the development of the biological engineering technology in recent years,the polypeptide drugs of the recombinant human growth factors is used in treatment of IBD.This article will review these new biological agents clinically used for IBD.
出处
《胃肠病学和肝病学杂志》
CAS
2012年第3期292-294,共3页
Chinese Journal of Gastroenterology and Hepatology
关键词
炎症性肠病
生长因子
治疗
Inflammatory bowel disease
Growth factor
Therapy
